Dad, 41, Diagnosed with Alzheimer's: 'You Feel Guilty That You're Doing That to the Kids'
Fraser, a 41-year-old dad, opened up about his experience with early-onset Alzheimer's after being diagnosed with the disease in 2024
On a YouTube channel, he tracks the symptoms that he experiences and how the illness is impacting his family
'You feel guilty that you're doing that to the kids,' he admitted, 'even though it's not your fault'A father with early-onset Alzheimer's disease is sharing how his symptoms began manifesting before his diagnosis — and when his family noticed something was wrong.
Fraser, a researcher from Australia, shares an honest look at his journey on his YouTube channel — I (don't) have dementia. The symptoms, he explained, began nearly two and a half years before his diagnosis in 2024.
'I remember I was having some pretty big memory flaws,' Fraser, 41, said in a video, sharing that one incident came when he sat down to watch a movie with his partner, who told him, ''We watched that, like, a month ago.' "
He continued, recalling, "Anyway I watched the whole movie and the ending was still a complete surprise — I had no memory of watching it, whatsoever.'
Another time, the dad to teenage girls shared that one daughter told him she was going to the movies with friends and would be out late.
'It came to nighttime and I started freaking out thinking, 'Where's my daughter?' Like, I was genuinely freaking out,' Fraser said.
Obviously, his kids noticed; he explained in another video: 'I asked my kids, just sort of casually, and they said, like, 'Everyone has memory issues that they have, they forget stuff in everyday life … we just noticed that you were just doing them more often, more frequently.' '
He shared that these days, he writes everything down in a diary as he struggles through 'every day scheduling,' explaining that if plans change, he can recall the original plan but not the revision.
Alzheimer's, the most commonly diagnosed form of dementia, is generally diagnosed in older adults, according to John Hopkins Medicine. Treatment can help slow the progression of the disease, but it's not known why some people, like Fraser, develop it early.
The ebb and flow of the symptoms, Fraser said in a recent video, can make you 'certain you have it and certain you do not have it.'
'It will change your identity,' he admitted, confessing that he can be 'selfish' and 'not follow through with [his] word.'
Fraser shared that when he's in later stages, 'I can largely be off with the fairies, thinking I'm hanging out with my kid friend in primary school.' He said he'd rather his loved ones 'just [go] along with it as opposed to trying to correct me all the time.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
But the hardest part, he added, is knowing how it's impacting his children.
'They're already having to make accommodations,' Fraser said in a video while on a retreat with other people who've been diagnosed with early-onset Alzheimer's. 'Being the parent, who's the one who's supposed to be supportive and the one who's supposed to be there for the kids … that whole issue of that sort of feeling like it's flipping a little bit.'
'You feel guilty that you're doing that to the kids,' he said, 'even though it's not your fault.'
Read the original article on People
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Dad, 41, Diagnosed with Alzheimer's: 'You Feel Guilty That You're Doing That to the Kids'
Fraser, a 41-year-old dad, opened up about his experience with early-onset Alzheimer's after being diagnosed with the disease in 2024 On a YouTube channel, he tracks the symptoms that he experiences and how the illness is impacting his family 'You feel guilty that you're doing that to the kids,' he admitted, 'even though it's not your fault'A father with early-onset Alzheimer's disease is sharing how his symptoms began manifesting before his diagnosis — and when his family noticed something was wrong. Fraser, a researcher from Australia, shares an honest look at his journey on his YouTube channel — I (don't) have dementia. The symptoms, he explained, began nearly two and a half years before his diagnosis in 2024. 'I remember I was having some pretty big memory flaws,' Fraser, 41, said in a video, sharing that one incident came when he sat down to watch a movie with his partner, who told him, ''We watched that, like, a month ago.' " He continued, recalling, "Anyway I watched the whole movie and the ending was still a complete surprise — I had no memory of watching it, whatsoever.' Another time, the dad to teenage girls shared that one daughter told him she was going to the movies with friends and would be out late. 'It came to nighttime and I started freaking out thinking, 'Where's my daughter?' Like, I was genuinely freaking out,' Fraser said. Obviously, his kids noticed; he explained in another video: 'I asked my kids, just sort of casually, and they said, like, 'Everyone has memory issues that they have, they forget stuff in everyday life … we just noticed that you were just doing them more often, more frequently.' ' He shared that these days, he writes everything down in a diary as he struggles through 'every day scheduling,' explaining that if plans change, he can recall the original plan but not the revision. Alzheimer's, the most commonly diagnosed form of dementia, is generally diagnosed in older adults, according to John Hopkins Medicine. Treatment can help slow the progression of the disease, but it's not known why some people, like Fraser, develop it early. The ebb and flow of the symptoms, Fraser said in a recent video, can make you 'certain you have it and certain you do not have it.' 'It will change your identity,' he admitted, confessing that he can be 'selfish' and 'not follow through with [his] word.' Fraser shared that when he's in later stages, 'I can largely be off with the fairies, thinking I'm hanging out with my kid friend in primary school.' He said he'd rather his loved ones 'just [go] along with it as opposed to trying to correct me all the time.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. But the hardest part, he added, is knowing how it's impacting his children. 'They're already having to make accommodations,' Fraser said in a video while on a retreat with other people who've been diagnosed with early-onset Alzheimer's. 'Being the parent, who's the one who's supposed to be supportive and the one who's supposed to be there for the kids … that whole issue of that sort of feeling like it's flipping a little bit.' 'You feel guilty that you're doing that to the kids,' he said, 'even though it's not your fault.' Read the original article on People
Business Wire
7 hours ago
- Business Wire
Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine
CHICAGO--(BUSINESS WIRE)--Building on a collaboration that spans more than three decades, GE HealthCare has renewed its research collaboration with Stanford Medicine – with one of their key intentions being the development and research of innovative total body PET/CT technology. i This effort is expected to explore new clinical pathways and help enhance patient outcomes through innovative imaging solutions. 'This technology is designed to offer a level of sensitivity and spatial resolution that can change how we design and conduct molecular imaging studies,' says Dr. Andrei Iagaru, Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. Share 'PET/CT has revolutionized the way we understand and treat disease by allowing us to visualize biological processes at the cellular level,' explains Dr. Quynh-Thu Le, interim Chair of the Department of Radiology, Stanford Medicine. 'With total body PET/CT, we can explore new frontiers. Not only do we expect it will be faster, but we also believe it will fundamentally expand what is possible in translational research.' Molecular imaging – and specifically the utilization of PET/CT scanners – offers opportunities for precision care across various disease states. It supports theranostics in oncology for advanced prostate cancer treatment, helps streamline radiation oncology workflows, aids in beta amyloid imaging for Alzheimer's evaluation and monitoring, and assists in myocardial perfusion evaluation for diagnosing coronary artery disease. Unlike other imaging procedures, PET/CT technology visualizes, characterizes, and quantifies biological processes at the cellular level, aiding in early disease identification, detailed assessment, and treatment planning. It is a non-invasive solution, providing critical insights that help enhance patient care and can support accelerated drug development. 'This technology is designed to offer a level of sensitivity and spatial resolution that can change how we design and conduct molecular imaging studies,' adds Dr. Andrei Iagaru, Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. 'For example, such technological characteristics can create opportunities to reduce anesthesia use in pediatric imaging by dramatically shortening scan times and enable the exploration of dual-tracer studies and early diagnosis with far greater precision. Total body PET/CT technology is an ideal tool to evaluate biodistribution and dosimetry of new PET radiopharmaceuticals in our first human studies.' Knowing the potential of this technology, researchers at Stanford Medicine and engineers at GE HealthCare aim to advance a next-generation PET/CT designed to provide new opportunities to improve diagnosis, staging, therapeutic planning, and evaluation of treatment response across various care pathways. By leveraging the technology's capabilities, both institutions believe it has the potential to drive new clinical pathways, expedite the development and translation of new diagnostic and therapeutic agents, support existing molecular imaging and theranostics applications, and promote enhanced healthcare system efficiency. 'The high throughput we anticipate from this technology could ultimately help improve access for our patients and reduce wait times to their next appointment,' says Dr. Erin Grady, incoming Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. GE HealthCare's total body PET/CT innovation In collaboration with a select group of leading healthcare institutions around the world, GE HealthCare aims to demonstrate how total body PET/CT imaging can overcome barriers that previously hindered widespread adoption of PET/CT beyond oncology. This initiative seeks to expand the use of PET with the goal of leveraging ultra-high sensitivity total body PET/CT technology to push the boundaries of oncology by significantly reducing scan time and the injected dose – important considerations for all patients, but particularly vulnerable patients like pediatrics, where ultra-fast scans can allow reduction in anesthesia and sedation in children. To support this advanced research, encourage new discoveries, and meet growing clinical demands, GE HealthCare designed its total body PET/CT technology with the goal of enabling ultra-low dose scans; fast acquisitions; multi organ dynamic imaging; and dual tracer imaging. All important factors that help improve diagnosis confidence. In parallel, the technology aims to improve healthcare system efficiency by enhancing clinical workflows, supporting routine clinical practice, and improving operational efficiency. 'At GE HealthCare, innovation is in our DNA. Our total body PET/CT technology represents the next chapter in our enduring commitment to advancing medical imaging,' adds Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. 'We're proud to collaborate with world-class institutions to explore new clinical frontiers in oncology and beyond. Together with our MIM software solutions, we're designing flexible, AI-enhanced tools that not only aim to enhance diagnostic confidence and operational efficiency but also help clinicians deliver more precise, personalized care that can truly improve patient outcomes.' GE HealthCare has a long-standing history of and commitment to pioneering next-generation imaging technology. From the first commercially available PET/CT solution, Discovery LS, ii to the development of the first silicon-based photon counting computed tomography (CT) prototype, iii GE HealthCare continues to push the boundaries of medical imaging for the benefit of clinicians and patients worldwide. As such, GE HealthCare is at the forefront of driving a connected healthcare transformation and revolutionizing precision care. For more information on GE HealthCare's impressive Molecular Imaging portfolio, visit About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.
Medscape
11 hours ago
- Medscape
NICE Rejects Alzheimer's Drugs Over Limited Benefit for Cost
Two new drugs to treat Alzheimer's disease have been rejected for NHS use in England and Wales because they are too expensive to justify their 'relatively small' benefits. In final draft guidance, the National Institute for Health and Care Excellence (NICE) said it could not recommend donanemab (Kisunla, Eli Lilly) or lecanemab (Leqembi, Eisai) for adults with mild cognitive impairment (MCI) or mild dementia caused by Alzheimer's disease. The guidance applies to adults who are either heterozygous for the apolipoprotein E4 gene or who do not carry it. The Alzheimer's Society described the decision as 'highly disappointing.' Professor Fiona Carragher, chief policy and research officer at the charity, said 'the science is flying but the system is failing.' Modest Benefits at High Cost Both drugs have been shown to slow cognitive decline. However, NICE concluded that the benefits were too small to justify the high costs to the NHS, including their administration. The decision upholds NICE's earlier position from March this year. Tackle Underlying Disease There are currently no pharmacologic treatments for MCI caused by Alzheimer's disease. Donanemab and lecanemab are monoclonal antibodies designed to reduce amyloid plaques in the brain. They aim to slow disease progression, unlike current treatments that only relieve symptoms. Donanemab is given monthly via IV infusion. Lecanemab is administered intravenously every 2 weeks. Clinical Evidence Considered Clinical evidence for donanemab came from the phase 3, randomised placebo-controlled double-blind TRAILBLAZER‑ALZ 2 trial, which included 1736 people aged 60-85 with early symptomatic Alzheimer's disease (MCI or mild dementia). Lecanemab was evaluated in the phase 3, randomised, placebo-controlled, superiority double-blind Clarity AD trial, involving 1795 people aged 50-90 with early Alzheimer's disease. Both trials showed that patients on active treatment continued to experience worsening cognitive function over time, but at a slower rate than those on placebo. Donanemab may have some sustained benefit after treatment ends, but for lecanemab, long-term outcomes remain unclear, the regulator said. Although both treatments delayed progression from mild to moderate Alzheimer's by 4-6 months, NICE concluded that this did not justify the overall costs of purchasing and administering the drugs. Impact on NHS Resources Helen Knight, director of medicines evaluation at NICE, said that significant NHS resources would be needed to enable access to the drugs. 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best,' she said. Knight added that NICE remained focused on the promising pipeline of new Alzheimer's drugs. The regulator said it would consider revisiting guidance on lecanemab once data on a subcutaneous reformulation become available. Hilary Evans-Newton, chief executive at Alzheimer's Research UK, described the rejection as a 'painful setback' for patients with Alzheimer's but not surprising given the 'modest benefits.' Rob Howard, professor of old age psychiatry at University College London noted to the Science Media Centre that the annual cost of the drugs and the safety monitoring required 'would have been close to the cost of a nurse's salary for each treated patient.' Charles Marshall, professor of clinical neurology at Queen Mary University of London, said more effective drugs are needed 'so that the magnitude of benefit becomes indisputable.' Evans-Newton noted that with more than 30 Alzheimer's drugs currently in late-stage trials globally, 'momentum is building.' However, the government needed to work with NICE, the NHS, and industry 'to pilot licensed drugs, gather more data, and prepare the health system for what's ahead,' she said. Registered stakeholders, including the manufacturers and patient groups, have until 8 July to appeal against NICE's final draft recommendations.
